Результати пошуку - Dolores Isla

Уточнити результати
  1. 1
    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts за авторством Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel

    Опубліковано 2011
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy

    The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy за авторством Ariel Ramírez-Labrada, Dolores Isla, Á. Artal, Maykel Arias, Antonio Rezusta, Julián Pardo, Eva M. Gálvez

    Опубліковано 2020
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  3. 3
    Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications

    Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications за авторством Javier de Castro, Rosario Dueñas García, Pilar Garrido, Dolores Isla, Bartomeu Massutí, Belén Blanca, Jorge Rodriguez Vazquez

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

    SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) за авторством Manuel Dómine, Teresa Morán, Dolores Isla, Juan Luis Gomez Marti, Ivana Sullivan, Mariano Provencio, M.E. Olmedo, Santiago Ponce, Ana Blasco, Manuel Cobo

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

    Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment за авторством Javier Martínez‐Trufero, Dolores Isla, Juan Carlos Adansa, Antonio Irigoyen López, Ricardo Hitt, Irene Gil-Arnáiz, J. Lambea, María José Lecumberri, Juan Jesús Cruz

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

    Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients за авторством Rafael Rosell, Kathleen D. Danenberg, V. Alberola, Gerold Bepler, José Javier Sánchez, Carlos Camps, Mariano Provencio, Dolores Isla, Miquel Tarón, Pilar Díz, Á. Artal

    Опубліковано 2004
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medi... за авторством Pilar Garrido, Esther Conde, Javier de Castro, Javier Gómez‐Román, Enriqueta Felip, Lara Pijuán, Dolores Isla, Julián Sanz‐Ortega, Luis Paz‐Ares, Fernando López‐Ríos

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Med... за авторством Dolores Isla, María D. Lozano, Luis Paz‐Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    SEOM Clinical Guideline for bone metastases from solid tumours (2016)

    SEOM Clinical Guideline for bone metastases from solid tumours (2016) за авторством Cristina Grávalos, César A. Rodríguez, Adriano de Paula Sabino, Miguel Ángel Seguí, Juan Antonio Virizuela, Alberto Carmona‐Bayonas, Javier Cassinello, Dolores Isla, Carlos Jara, Miguel Martín

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer

    Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer за авторством Dolores Isla, Carme Sarries, Rafael Rosell, G. Alonso, Manuel Dómine, Miquel Tarón, Guillermo López-Vivanco, Carlos Camps, Mónica Botia, L. Núñez, M. Sánchez-Ronco, José Javier Sánchez, M. López-Brea, I. Barneto, Alfredo Paredes, B. Medina, Á. Artal, P. Lianes

    Опубліковано 2004
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

    Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients за авторством R. de las Peñas, M. Sánchez-Ronco, Vicente Alberola, Miquel Tarón, Carlos Camps, Rocio García‐Carbonero, Bartomeu Massutí, Cristina Queralt, Mónica Botia, Ronald G. García, Dolores Isla, Manuel Cobo, Mariacarmela Santarpía, Fabiana Letizia Cecere, Pedro Méndez, José Javier Sánchez, Rafael Rosell

    Опубліковано 2006
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

    Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers за авторством Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier de Castro, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, Thomas E. Stinchcombe

    Опубліковано 2018
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

    Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial за авторством Carlos Camps, Bartomeu Massutí, Ángel Martín Jiménez, I. Maestu, Ramón García Gómez, Dolores Isla, Jesús González, D. Almenar, Ana Blasco, Rafael Rosell, Alfredo Carrato, Núria Viñolas, N. Batista, Carlos García Girón, António Galán de Mera, M López, R. Blanco, Mariano Provencio, Pilar Díz, Enriqueta Felip

    Опубліковано 2005
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

    Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation за авторством R. Porta, J.M. Sánchez-Torres, Luis Paz‐Ares, Bartomeu Massutí, Noemı́ Reguart, Clara Mayo, P. Lianes, Cristina Queralt, Vicente Guillém, Pedro Salinas, S. Catot, Dolores Isla, Anna Pradas, Alfonso Gúrpide, Javier de Castro, Elena Simón Polo, Teresa Puig, Miguel Tarón, Rámón Colomer, Rafael Rosell

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901

    Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer... за авторством Pilar Garrido, J.L. González-Larriba, Amelia Insa, Mariano Provencio, Antonio Torres, Dolores Isla, José Miguel Sánchez, Felipe Cardenal, Manuel Dómine, Ramón Barceló, Vicente Tarrazona, A. Varela, Rafael Aguiló, Julio Astudillo, Ignacio Muguruza, Á. Artal, Florentino Hernándo, Bartomeu Massutí, María Sanchez-Ronco, Rafael Rosell

    Опубліковано 2007
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

    VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Ra... за авторством L. Paz-Ares, E O’Brien, M. Mauer, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martínez‐Martí, Martin Faehling, Masahiro Tsuboi, JS Lee, Kouichi Nakagawa, Jiong Yang, S.M. Keller, Nitish Jha, Sandrine Marréaud, R.A. Stahel, Solange Peters, Benjamin Besse

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

    Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer за авторством Enriqueta Felip, Rafael Rosell, J Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, José Manuel Borro, J.L. González-Larriba, Antonio Torres, Carlos Camps, Ricardo Guijarro, Dolores Isla, Rafael Aguiló, Vicente Alberola, José Padilla, Abel Sánchez‐Palencia, José Javier Sánchez, Eduardo Hermosilla, Bartomeu Massutí

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

    Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer за авторством S. Simonetti, Miguel Ángel Molina‐Vila, Cristina Queralt, Itziar de Aguirre, Clara Mayo, Jordi Bertran-Alamillo, José Javier Sánchez, J.L. González-Larriba, Ulpiano Jiménez, Dolores Isla, Teresa Morán, Santiago Viteri, Carlos Camps, Rosario Garcı́a-Campelo, Bartomeu Massutí, Susana Benlloch, Santiago Ramón y Cajal, Miquel Tarón, Rafael Rosell

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophos... за авторством Miguel Martín, Aña Lluch, Miguel Ángel Seguí, A. Ruíz, Manuel Ramos, Encarna Adrover, Álvaro Rodríguez-Lescure, Regina Große, Lourdes Calvo, Concepción Fernández‐Chacón, Montserrat Roset, A. Antón, Dolores Isla, Purificación Martínez del Prado, L. Iglesias, J. Załuski, Àngels Arcusa, José Manuel López-Vega, Montserrat Muñoz, J. R. Mel

    Опубліковано 2006
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

    CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations за авторством Enriqueta Felip, Andrea Ardizzoni, Tudor‐Eliade Ciuleanu, Manuel Cobo, К. К. Лактионов, Mária Szilasi, Raffaele Califano, Enric Carcereny, Richard W. Griffiths, Luis Paz‐Ares, Renata Duchnowska, M. Alonso Garcìa, Dolores Isla, Jacek Jassem, W. Appel, Janusz Milanowski, Jan P. van Meerbeeck, Juergen Wolf, Ang Li, A. Acevedo, Sanjay Popat

    Опубліковано 2020
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: